Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Sangel Capital
company
About
one of the earliest globally operating professional biomedical venture capital institutions in China
Highlights
Details
- Operating Status
- Active
- Investor Type
- Venture Capital
Sangel Capital as one of the earliest globally operating professional biomedical venture capital institutions was established in China in 2010, focusing on life science and technology, and having leading professional advantages and rich project resources in the biomedical investment industry. Sangel Capital has offices in Shenzhen, Beijing, Suzhou, and Chicago. We bring together a group of investment and advisory teams composed of industry experts, scientists, and investors in the field of life technology to manage and operate a series of RMB and USD funds.
Investments
Number of Investments
Number of Lead Investments
2
0
Sangel Capital has made 2 investments. Their most recent investment was on
Oct 23, 2020, when Sirnaomics raised $105M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Oct 23, 2020
Sirnaomics
|
Series D | $105M | Biopharma | — |
|
Oct 19, 2020
3D Medicines
|
Private Equity（PE） | ¥1.50B | Biopharma | — |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
